TB-500 FAQ: the questions, answered from the literature

Identity and definitions

Direct answers to the most-asked TB-500 questions, each grounded in the cited literature on the Ac-LKKTETQ fragment and its parent protein, thymosin beta-4.

What is TB-500?

TB-500 is the synthetic N-acetylated heptapeptide Ac-LKKTETQ — residues 17–23, the actin-binding motif, of the 43-amino-acid protein thymosin beta-4 ^[1]. Most efficacy data are on full-length Tβ4 (~4963 Da), not the 7-mer (~889 Da), so the two are easily conflated ^[5]. The fragment is a research and veterinary-context substance with no approved human use.

What does TB-500 stand for and what does TB stand for in TB-500?

TB is a thymosin-beta designation. TB-500 denotes the LKKTETQ actin-binding fragment of thymosin beta-4, supplied as a research and veterinary peptide ^[1]. The number is a product designation rather than a chemical identifier; the molecule is precisely named by its sequence, Ac-LKKTETQ.

What is TB-500 used for in research?

In research it is studied for tissue repair, cell migration, and angiogenesis, and — as full-length Tβ4 — for cardiac, neurological, and hair-follicle endpoints in animal models ^[5]. None of these is an approved human use; all are research findings, most in rodents.

Mechanism and angiogenesis

How does TB-500 work?

The LKKTETQ motif binds monomeric (G-) actin 1:1, capping both ends to buffer the unpolymerized actin pool and regulate cytoskeletal dynamics, cell migration, and motility ^[1]. That actin-sequestration step is the mechanistic hub; the migration, angiogenesis, and survival effects attributed to thymosin beta-4 are downstream of it.

Does TB-500 promote angiogenesis and is that a safety concern?

Thymosin beta-4 promotes endothelial migration and angiogenesis — a 2007 review surveys these modes of action ^[7] — and it cuts both ways. The same pro-angiogenic activity that aids repair is part of the theoretical tumor-safety concern, because Tβ4 is overexpressed in some cancers and implicated in metastasis and angiogenesis ^[5].

Does TB-500 increase VEGF and new blood vessel formation?

In vitro, thymosin beta-4 induced VEGF in a HIF-1α-dependent manner ^[8], and a combined rodent study reported concurrent angiogenesis with wound-healing and hair-follicle effects ^[12]. The evidence is preclinical, and largely on full-length Tβ4 rather than the heptapeptide.

Does TB-500 reduce inflammation?

Thymosin beta-4 has anti-inflammatory and pro-resolving activity (NF-κB / IL-8 suppression in vitro) and anti-fibrotic effects in animal models ^[5]. The data are preclinical, with no established human anti-inflammatory endpoint for the fragment.

Efficacy across tissues

Does TB-500 work for muscle tears and recovery from exercise?

Animal evidence is mixed. Thymosin beta-4 acts as a myoblast chemoattractant, but a 6-month mdx-mouse study found more regenerating fibers without strength or cardiac-function gains ^[5]. No human efficacy data exist for the fragment.

Can TB-500 help with tendon injuries and ligament repair?

The rationale rests on thymosin beta-4 recruiting myoblasts to injured muscle and its broad repair biology ^[5]; direct connective-tissue evidence is limited and animal-only. No human efficacy data exist for the fragment, so tendon and ligament claims are extrapolations from the migration and wound record.

Does TB-500 help wound healing?

In animal models, yes — topical or intraperitoneal Tβ4 accelerated dermal re-epithelialization and contraction (+42% at 4 days, +61% at 7 days in rats) ^[3], and recent delivery systems improved vascularized wound repair ^[15]. Human wound data are limited to full-length Tβ4 formulations.

How long does it take for TB-500 to work for injury healing?

Timelines come from animal models — for example +42% re-epithelialization at 4 days and +61% at 7 days in a rat wound study ^[3]. No validated human healing timeline exists for the fragment, and community-circulated timeframes are not from controlled trials.

Does TB-500 affect the heart?

In mice, Tβ4 activated PINCH–ILK–Akt survival signaling, improved early cardiomyocyte survival and cardiac function after coronary ligation ^[2], and engineered scaffold delivery promoted cardiac repair ^[14] — but a porcine study showed no benefit against ischemia-reperfusion injury ^[5]. The cardiac evidence is animal-only and not uniformly positive.

Does TB-500 have neuroprotective effects on the brain?

In rat stroke and TBI models, Tβ4 improved neurological outcome, but the embolic-stroke dose-response was non-monotonic: benefit at 2 and 12 mg/kg, none at 18 mg/kg ^[4]. Animal-only, and higher was not better.

Does TB-500 increase hair growth?

In rats and mice, thymosin beta-4 accelerated hair growth by activating hair-follicle bulge stem cells ^[11]. It is a rodent research finding, not a human hair-loss treatment, and the studies used full-length Tβ4.

Safety, evidence, and the human-data gap

What are the side effects of TB-500?

Human safety data for the fragment are scarce. The main theoretical concern is the tumor/angiogenesis signal — the same pro-migratory, pro-angiogenic biology that aids repair ^[5]. IV full-length Tβ4 was well tolerated to 1260 mg in a Phase 1 study ^[6], but that is the parent protein, not the 7-mer, so it does not establish the fragment's safety profile.

Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 is overexpressed in some cancers (for example pancreatic and colorectal) and implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic biology that aids repair is a theoretical tumor-safety concern ^[5]. Human safety data for the fragment are scarce, so this is a flagged caution rather than a quantified risk.

Is TB-500 safe for long-term use?

There are no long-term human studies of the TB-500 fragment. Long-term safety is unknown, and the tumor/angiogenesis signal means caution is warranted ^[5]. It remains a research-use substance, and no chronic human safety dataset exists for the heptapeptide.

Are there any human clinical trials on TB-500?

No completed controlled trials exist for the TB-500 fragment. Human data are limited to full-length Tβ4 — an IV Phase 1 safety study ^[6] and topical ophthalmic RCTs. A 2026 Sports Medicine review lists TB-500 as unapproved with scarce human safety data ^[10].

What is the difference between TB-500 and BPC-157?

Both are unapproved research peptides studied for tissue repair, with distinct sequences and mechanisms — Tβ4's actin-binding fragment ^[1] versus BPC-157's pentadecapeptide. The 2026 Sports Medicine review lists both as unapproved with limited human data ^[10]. They are compared because of shared status, not a demonstrated combined effect.

Regulatory and access

Is TB-500 FDA approved?

No. TB-500 has no FDA-approved therapeutic indication and sits in 503A Category 2 (bulk substances that may present significant safety risks), outside FDA's enforcement-discretion policy for compounding ^[16]. See the TB-500 legal status page for the full FDA 503A standing and the July 2026 PCAC agenda.

Is TB-500 banned by WADA and in competitive sports?

Yes. TB-500 falls under WADA's prohibited peptide/growth-factor and tissue-repair categories and is detected by LC-MS anti-doping assays ^[5]. It is banned in and out of competition for the relevant classes.

Is TB-500 legal?

"Legal" depends on context. As an FDA matter, TB-500 is not an approved drug and sits in 503A Category 2, outside the enforcement-discretion policy while that status stands ^[16]; in sport it is WADA-prohibited ^[5]; some jurisdictions classify it as a prescription medicine. This is general information, not legal advice — the TB-500 legal status page covers the U.S. landscape.

Can you get TB-500 from a compounding pharmacy?

Compounded access generally requires a licensed-prescriber evaluation, a valid patient-specific prescription, and an eligible active ingredient at a 503A pharmacy or 503B outsourcing facility ^[20]. A Category 2 substance is not eligible for routine 503A compounding while that status stands, which applies to TB-500 today ^[16].

What is the FDA 503A status of TB-500?

FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 — effective with its September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information ^[16]. "TB-500 (free base)" and "TB-500 acetate" are on the July 23–24, 2026 PCAC agenda for consideration, which is a scheduled evaluation, not a decision ^[18].

Why is TB-500 used in racehorses?

TB-500 was encountered as a designer tissue-repair drug in racehorses, prompting equine LC-MS detection methods ^[5]. It is used in a veterinary and doping context, not as an approved equine medicine.